Display options
Cite
Meyer F, Latour J, Cools AR, et al. Noradrenaline-induced release of newly-synthesized accumbal dopamine: differential role of alpha- and beta-adrenoceptors. Front Cell Neurosci. 2014;8:243doi: 10.3389/fncel.2014.00243.
Meyer, F., Latour, J., Cools, A. R., & Verheij, M. M. (2014). Noradrenaline-induced release of newly-synthesized accumbal dopamine: differential role of alpha- and beta-adrenoceptors. Frontiers in cellular neuroscience, 8243. https://doi.org/10.3389/fncel.2014.00243
Meyer, Francisca, et al. "Noradrenaline-induced release of newly-synthesized accumbal dopamine: differential role of alpha- and beta-adrenoceptors." Frontiers in cellular neuroscience vol. 8 (2014): 243. doi: https://doi.org/10.3389/fncel.2014.00243
Meyer F, Latour J, Cools AR, Verheij MM. Noradrenaline-induced release of newly-synthesized accumbal dopamine: differential role of alpha- and beta-adrenoceptors. Front Cell Neurosci. 2014 Aug 21;8:243. doi: 10.3389/fncel.2014.00243. eCollection 2014. PMID: 25309315; PMCID: PMC4162431.
Copy Download .nbib Format: NLM
Share it on

Front Cell Neurosci. 2014 Aug 21;8:243. doi: 10.3389/fncel.2014.00243. eCollection 2014.

Noradrenaline-induced release of newly-synthesized accumbal dopamine: differential role of alpha- and beta-adrenoceptors.

Frontiers in cellular neuroscience

Francisca Meyer, Judith Latour, Alexander R Cools, Michel M M Verheij

Affiliations

  1. Department of Molecular Animal Physiology, Donders Institute for Brain, Cognition and Behaviour, Nijmegen Center for Molecular Life Sciences, Radboud University Nijmegen Nijmegen, Netherlands.
  2. Department of Cognitive Neuroscience, Donders Institute for Brain, Cognition and Behaviour, Radboud University Nijmegen Medical Centre Nijmegen, Netherlands.
  3. Department of Molecular Animal Physiology, Donders Institute for Brain, Cognition and Behaviour, Nijmegen Center for Molecular Life Sciences, Radboud University Nijmegen Nijmegen, Netherlands ; Department of Cognitive Neuroscience, Donders Institute for Brain, Cognition and Behaviour, Radboud University Nijmegen Medical Centre Nijmegen, Netherlands.

PMID: 25309315 PMCID: PMC4162431 DOI: 10.3389/fncel.2014.00243

Abstract

Previous studies have shown that intra-accumbens infusion of isoproterenol (ISO), a beta-adrenoceptor-agonist, and phenylephrine (PE), an alpha-adrenoceptor-agonist, increase the release of accumbal dopamine (DA). In the present study we analyzed whether the ISO-induced release of DA is sensitive to pretreatment with the DA synthesis inhibitor alpha-methyl-para-tyrosine (AMPT). Earlier studies have shown that the PE-induced release of DA is derived from DA pools that are resistant to AMPT. In addition to PE, the alpha-adrenoceptor-antagonist phentolamine (PA) was also found to increase accumbal DA release. Therefore, we investigated whether similar to the DA-increasing effect of PE, the DA increase induced by PA is resistant to AMPT. Pretreatment with AMPT prevented the ISO-induced increase of accumbal DA. The accumbal DA increase after PA was not reduced by the DA synthesis inhibitor, independently of the amount of DA released. These results show that mesolimbic beta-, but not alpha-adrenoceptors, control the release of accumbal newly-synthesized DA pools. The DA-increasing effects of PE have previously been ascribed to stimulation of presynaptic receptors located on noradrenergic terminals, whereas the DA-increasing effects of PA and ISO have been ascribed to an action of these drugs at postsynaptic receptors on dopaminergic terminals. The fact that AMPT did not affect the accumbal DA response to PE and PA, whereas it did prevent the accumbal DA increase to ISO, supports our previously reported hypothesis that the noradrenergic neurons of the nucleus accumbens containing presynaptic alpha-adrenoceptors impinge upon the dopaminergic terminals in the nucleus accumbens containing postsynaptic adrenoceptors of the alpha but not of the beta type. The putative therapeutic effects of noradrenergic agents in the treatment of DA-related disorders are shortly discussed.

Keywords: alpha-adrenoceptors; alpha-methyl-para-tyrosine; beta-adrenoceptors; isoproterenol; noradrenaline-dopamine interactions; norepinephrine-dopamine interactions; nucleus accumbens; phentolamine

References

  1. Curr Pharm Des. 2010;16(5):488-501 - PubMed
  2. Eur J Pharmacol. 2008 May 13;585(2-3):228-44 - PubMed
  3. J Neurochem. 2008 Jun 1;105(6):2122-33 - PubMed
  4. Neuroscience. 1999;88(4):1153-63 - PubMed
  5. J Clin Psychopharmacol. 1995 Feb;15(1):63-78 - PubMed
  6. Handb Exp Pharmacol. 2012;(212):1-26 - PubMed
  7. Behav Pharmacol. 1997 Jun;8(2-3):113-23 - PubMed
  8. Pharmacol Biochem Behav. 1998 May;60(1):151-9 - PubMed
  9. Psychopharmacologia. 1975;41(2):175-80 - PubMed
  10. Eur J Pharmacol. 2012 Aug 5;688(1-3):35-41 - PubMed
  11. Annu Rev Med. 2013;64:393-406 - PubMed
  12. Physiol Behav. 2011 Jul 25;104(1):168-72 - PubMed
  13. Neuroscience. 2009 Sep 15;162(4):1163-73 - PubMed
  14. Psychopharmacology (Berl). 2009 Aug;205(3):441-55 - PubMed
  15. Front Psychiatry. 2011 Nov 29;2:64 - PubMed
  16. Eur J Neurosci. 2006 Mar;23(5):1332-40 - PubMed
  17. Psychopharmacology (Berl). 1997 Jul;132(2):181-7 - PubMed
  18. Eur J Pharmacol. 2007 Jan 12;554(2-3):175-82 - PubMed
  19. Neuropsychopharmacology. 2013 Feb;38(3):540-1 - PubMed
  20. Science. 1983 Jul 8;221(4606):169-71 - PubMed
  21. Neuropsychopharmacology. 2011 Apr;36(5):1003-14 - PubMed
  22. Neurochem Res. 1984 Sep;9(9):1231-8 - PubMed
  23. Neuroscience. 2000;99(1):55-64 - PubMed
  24. Behav Neurosci. 2000 Dec;114(6):1088-95 - PubMed
  25. Behav Neurosci. 1994 Dec;108(6):1107-18 - PubMed
  26. Curr Med Chem. 2004 Feb;11(3):343-58 - PubMed
  27. Neuropsychobiology. 1996;34(3):136-45 - PubMed
  28. J Oral Sci. 2005 Dec;47(4):185-90 - PubMed
  29. Ann Pharmacother. 1999 Apr;33(4):480-8 - PubMed
  30. J Neurochem. 2007 Feb;100(3):810-21 - PubMed
  31. Psychopharmacology (Berl). 1976 Jul 28;48(2):225-31 - PubMed
  32. Learn Mem. 2011 May 20;18(6):405-13 - PubMed
  33. Neurobiol Learn Mem. 2008 Jan;89(1):47-60 - PubMed
  34. Brain Res. 1989 Oct 16;499(2):205-13 - PubMed
  35. Science. 1989 Sep 29;245(4925):1511-3 - PubMed
  36. Behav Pharmacol. 2015 Feb;26(1-2):81-90 - PubMed
  37. J Psychopharmacol. 2005 Jul;19(4):408-13 - PubMed
  38. Behav Neurosci. 2002 Dec;116(6):1084-92 - PubMed
  39. Neuropsychologia. 1995 Sep;33(9):1143-53 - PubMed
  40. Eur J Pharmacol. 2008 Dec 28;601(1-3):94-8 - PubMed
  41. Brain Res Bull. 1990 Jan;24(1):49-69 - PubMed
  42. Neuropsychopharmacology. 2010 Nov;35(12):2346-56 - PubMed
  43. Neurology. 2002 Feb 26;58(4 Suppl 1):S1-8 - PubMed
  44. Neurochem Res. 1993 Mar;18(3):285-9 - PubMed
  45. Pharmacol Biochem Behav. 2011 Mar;98(1):43-53 - PubMed
  46. Behav Brain Res. 1987 Jul;25(1):49-61 - PubMed
  47. J Neural Transm (Vienna). 2009 Apr;116(4):389-94 - PubMed
  48. Expert Opin Pharmacother. 2001 Apr;2(4):557-72 - PubMed
  49. J Neurochem. 2004 Oct;91(1):49-56 - PubMed
  50. Nat Neurosci. 2005 Nov;8(11):1481-9 - PubMed
  51. Mov Disord. 2011 Mar;26(4):587-98 - PubMed
  52. Psychopharmacology (Berl). 2002 Oct;163(3-4):265-82 - PubMed
  53. Arch Neurol. 2004 Jul;61(7):1009-12 - PubMed
  54. Exp Neurol. 2005 Jan;191(1):24-32 - PubMed
  55. J Neural Transm (Vienna). 2007 Sep;114(9):1135-42 - PubMed
  56. Trends Pharmacol Sci. 1992 May;13(5):177-84 - PubMed
  57. Annu Rev Pharmacol Toxicol. 2001;41:237-60 - PubMed
  58. Neurology. 1998 Aug;51(2 Suppl 2):S2-9 - PubMed
  59. Eur J Pharmacol. 2013 Sep 5;715(1-3):363-9 - PubMed
  60. Neuropsychopharmacology. 2012 Aug;37(9):2161-72 - PubMed
  61. Neuropharmacology. 2012 Jan;62(1):427-35 - PubMed

Publication Types